{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:24:28Z","timestamp":1787761468618,"version":"build-2784847793"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2025,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tyrosine kinase inhibitors (TKIs) and blinatumomab have improved outcomes in Philadelphia\u2010positive B\u2010lymphoblastic leukemia (Ph\u2009+\u2009B\u2010ALL). However, the efficacy of TKI and blinatumomab as a standalone regimen compared to the standard chemotherapy\u2010plus\u2010TKI approach remains uncertain. We conducted a single\u2010center retrospective analysis of 47 patients, including 18 treated with TKI and blinatumomab (de novo:\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200913; relapsed:\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20095) and 29 treated with chemotherapy and TKI. Patients in the blinatumomab cohort were significantly older (median age 65\u2009years vs. 48\u2009years), had higher rates of active central nervous system disease (27.7% vs. 0%) and were less frequently consolidated with allogeneic stem cell transplantation (33% vs. 79%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u2009.05). Despite these differences, overall survival (2\u2010year OS: 87% vs. 78%), progression\u2010free survival (PFS: 81% vs. 54%), and non\u2010relapse mortality (NRM: 6.3% vs. 14%) were comparable. Severe treatment\u2010related adverse events were significantly less frequent in the TKI and blinatumomab cohort, with no difference in early molecular complete response rates. Our findings, consistent with published prospective trials, highlight the safety and efficacy of TKI and blinatumomab in managing Ph\u2009+\u2009B\u2010ALL.\n                  <\/jats:p>","DOI":"10.1002\/ijc.35468","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:59:23Z","timestamp":1745989163000},"page":"1197-1204","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tyrosine kinase inhibitors with blinatumomab versus chemotherapy in Philadelphia\u2010positive acute B\u2010lymphoblastic leukemia"],"prefix":"10.1002","volume":"157","author":[{"given":"Sebastian M.","family":"Stolz","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Hofer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"R\u00f6sler","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Deuel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel","family":"Schwotzer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Schneidawind","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Schneidawind","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-4547","authenticated-orcid":false,"given":"Max J.","family":"Rieger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2398"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010158934"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201002\u2010627935"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v112.11.2931.2931"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)71170\u20102"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201008\u2010798322"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.S004"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25338"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26949"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2016272"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01075"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00319\u20102"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00272"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023502"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34612"},{"key":"e_1_2_12_21_1","volume-title":"RStudio: Integrated Development for R","author":"RStudio Team","year":"2020"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010189632"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.4783"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34667"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01405"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00108"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010170579"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010162475"},{"key":"e_1_2_12_29_1","unstructured":"Study Details | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT04722848?cond=PhiladelphiaPositiveAcuteLymphoblasticLeukemia&intr=transplantation&aggFilters=status:notrec&rank=5. Accessed July 28 2024"},{"key":"e_1_2_12_30_1","unstructured":"Study Details | Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy Imatinib or Ponatinib Blinatumomab and SCT | ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT06061094?cond=PhiladelphiaPositiveAcuteLymphoblasticLeukemia&intr=transplantation&aggFilters=status:notrec&rank=1. Accessed July 28 2024"},{"key":"e_1_2_12_31_1","unstructured":"Study Details | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR\u2010ABL\u2010Positive Acute Lymphoblastic Leukemia in Adults | ClinicalTrials.gov.https:\/\/clinicaltrials.gov\/study\/NCT04530565#study-overview. Accessed March 9 2025"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010207892"},{"key":"e_1_2_12_33_1","unstructured":"View of Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC).https:\/\/smw.ch\/index.php\/smw\/article\/view\/4289\/6092. Accessed March 9 2025"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.35468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.35468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.35468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:54:45Z","timestamp":1787759685000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.35468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9,15]]}},"alternative-id":["10.1002\/ijc.35468"],"URL":"https:\/\/doi.org\/10.1002\/ijc.35468","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2024-12-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}